title: Peritoneal tuberculosis after imatinib therapy.
authors.forename: Laurence
authors.initials: L
authors.lastname: Senn
authors.forename: Tibor
authors.initials: T
authors.lastname: Kovacsovics
authors.forename: Philip E
authors.initials: PE
authors.lastname: Tarr
authors.forename: Pascal
authors.initials: P
authors.lastname: Meylan
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D009894:Opportunistic Infections / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D010538:Peritonitis / Q000382:microbiology; D014395:Peritonitis, Tuberculous / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D000995:Antitubercular Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate